The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Serum Interleukin 6 Levels May Predict Presentation of IgG4-Related Disease

Serum Interleukin 6 Levels May Predict Presentation of IgG4-Related Disease

May 11, 2020 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Interleukin (IL) 6 plays multiple roles in immune response, including promoting the activation and differentiation of T cells and B cells. The presence of IL-6 is also associated with some rheumatic diseases. Examples: The hyperproduction of IL-6 in lymphoid tissue causes multicentric Castleman’s disease (MCD), a polyclonal lymphoproliferative disorder associated with hepatomegaly and/or splenomegaly. Rheumatologists have found patients with anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) tend to have numerous immunopositive cells for IL-6 in their affected organs. Additionally, research has shown some patients with IgG4-related disease (IgG4-RD) have clinical and histopathological presentations similar to those of patients with MCD and AAV, although patients with IgG4-RD rarely present with swelling of the liver and spleen.

You Might Also Like
  • Gene Signatures in IgG4-Related Disease
  • International Consensus Statement on the Management & Treatment of IgG4-Related Disease
  • Draft Classification Criteria for IgG4-Related Disease Introduced
Also By This Author
  • Abaloparatide vs. Alendronate for Osteoporosis

Recent research suggests serum IL-6 levels at the onset of IgG4-RD correlate with clinical inflammatory parameters, such as serum levels of C-reactive protein (CRP), hemoglobin and albumin. However, the significant correlation between IL-6 level and IgG4 level is unknown. The research by Satoshi Tsukuda, PhD, assistant professor of gastroenterology and hepatology at the Kansai Medical University, Japan, and colleagues indicates serum IL-6 may be associated with involvement of the bile duct, liver and spleen. This association between splenic enlargement and higher serum IL-6 occurs even in the absence of cirrhosis and extrahepatic obstruction of the portal vein. The investigators published their findings online Jan. 17 in PLoS One.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The retrospective study included 43 patients with IgG4-RD who were diagnosed in accordance with the current criteria. The cohort included a heterogeneous group of patients with multiple underlying pathogenic components. The affected organs associated with IgG4-RD were the lacrimal gland (4%), salivary gland (37%), pancreas (86%), biliary tract (63%), liver (9%), spleen (16%), kidney (19%), retroperitoneum (9%), lymph node (49%) and aorta (2%). The researchers reported a median serum IL-6 level of 2.2 pg/mL, a median CRP level of 0.10 mg/dL and a median IgG4 level of 290 mg/dL.

The investigators divided the patients into two groups using an IL-6 cut-off of 4 pg/mL. They found the high IL-6 group (n=10) was older, had lower albumin and had higher CRP and higher aspartate aminotransferase (AST) than the low IL-6 group (n=33). Although the low IL-6 group had significantly more salivary gland involvement (46%) than the high IL-6 group (10%), there was significantly more hepatic swelling, kidney swelling and splenomegaly in the high IL-6 group compared with the low IL-6 group (liver: 40% vs. 0%; kidney: 40% vs. 12%; spleen 40% vs. 9%). Also, biliary tract involvement was more common in the high IL-6 group (90% vs. 58%), but the difference was not statistically significant.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: Conditions Tagged With: IgG4 related disease, IgG4-RD, IL-6

You Might Also Like:
  • Gene Signatures in IgG4-Related Disease
  • International Consensus Statement on the Management & Treatment of IgG4-Related Disease
  • Draft Classification Criteria for IgG4-Related Disease Introduced
  • IgG4-Related Kidney Disease: Diagnostics, Manifestations & More

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.